Incidence and management of CRS and neurotoxicity
| . | Group 1 (n = 11) . | Group 2 (n = 18) . | P . |
|---|---|---|---|
| CRS | |||
| Any grade, n (%) | 5 (45) | 7 (39) | 1 |
| Grade ≥3, n (%) | 1 (9)∗ | 1 (6)† | 1 |
| Median time to onset, d (range) | 4 (1-6) | 6 (3-10) | .05 |
| Median duration, d (range) | 8 (5-19) | 3 (1-20) | .08 |
| Neurotoxicity | |||
| Any grade, n (%) | 3 (27) | 2 (11) | .34 |
| Grade ≥3, n (%) | 1 (9)∗ | 1 (6)‡ | 1 |
| Treatment for CRS and neurotoxicity | |||
| Tocilizumab, n (%) | 1 (9) | 1 (6) | 1 |
| Steroids, n (%) | 1 (9) | 2 (11) | 1 |
| Tocilizumab and steroids, n (%) | 1 (9) | 1 (6) | 1 |
| . | Group 1 (n = 11) . | Group 2 (n = 18) . | P . |
|---|---|---|---|
| CRS | |||
| Any grade, n (%) | 5 (45) | 7 (39) | 1 |
| Grade ≥3, n (%) | 1 (9)∗ | 1 (6)† | 1 |
| Median time to onset, d (range) | 4 (1-6) | 6 (3-10) | .05 |
| Median duration, d (range) | 8 (5-19) | 3 (1-20) | .08 |
| Neurotoxicity | |||
| Any grade, n (%) | 3 (27) | 2 (11) | .34 |
| Grade ≥3, n (%) | 1 (9)∗ | 1 (6)‡ | 1 |
| Treatment for CRS and neurotoxicity | |||
| Tocilizumab, n (%) | 1 (9) | 1 (6) | 1 |
| Steroids, n (%) | 1 (9) | 2 (11) | 1 |
| Tocilizumab and steroids, n (%) | 1 (9) | 1 (6) | 1 |
CRS was graded according to the Lee criteria. Neurotoxicity was graded using the CTCAE v4.03. P values per Wilcoxon rank-sum test or Fisher exact test (2-sided), as appropriate.
Patient with grade 5 CRS and neurotoxicity who did not receive any durvalumab dose.
Patient from durvalumab 225 mg dose level with grade 4 CRS (DLT).
Patient from durvalumab 750 mg dose level with prolonged grade 3 neurotoxicity (DLT).